Israeli biotech firm surges on mystery firm's nameless analyst note
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Tel Aviv
WHEN Pluristem Therapeutics Inc, an Israeli developer of experimental stem-cell treatments, rose 39 per cent in Nasdaq trading last week, traders attributed it to a bullish report on a website linked to a California biotech pundit.
The two-page report from Acceleron Equity Research dated Jan 26 was published on Acceleron's website and distributed by Marketwired, a press-release distribution service, the next day. The site and research document don't identify anyone involved with the firm, while the press release about the report lists a media contact named M Morhamus. The report says the analysts who wrote it don't own Pluristem stock, but that employees and officers of Acceleron might.
Share with us your feedback on BT's products and services
TRENDING NOW
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
‘Largest Singapore commercial S-Reit proxy’: analysts say buy CICT shares after Paragon acquisition
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
